Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance

BACKGROUND: Primary prostate cancers are infiltrated with PD-1 expressing CD8+ T cells. However, in early clinical trials, men with mCRPC did not respond to PD-1 blockade as a monotherapy. One explanation for this unresponsiveness could be that prostate tumors generally do not express PD-L1, the pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Allison M., Nirschl, Thomas R., Nirschl, Christopher J., Francica, Brian J., Kochel, Christina M., van Bokhoven, Adrie, Meeker, Alan K., Lucia, M. Scott, Anders, Robert A., DeMarzo, Angelo M., Drake, Charles G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641011/
https://www.ncbi.nlm.nih.gov/pubmed/26260996
http://dx.doi.org/10.1038/pcan.2015.39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641011/
https://www.ncbi.nlm.nih.gov/pubmed/26260996
http://dx.doi.org/10.1038/pcan.2015.39

Ejemplares similares